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The scholarly paper on 'History of cardiology in India' is a
revealing account of how cardiology developed in India over
a period of some 70 years with valuable information on 'Indian
Heritage of Cardiovascular Sciences'.1 Few points need worth
mentioning. It is correct that out of four Vedas, namely
Rigveda, Samveda, Yajurveda, and Atharwaveda, Ayurveda
owes its origin mostly to Atharwaveda.2 However, there is a bit
of spelling mix-up in the text; Rigveda has been spelt as Rik,
Samveda as Sham, and Yajurveda as Yadu. Further, Sushruta,
though primarily a surgeon, was the ﬁrst to give the concept of
atherosclerosis, diabetes, and angina and the role of exercise
in prevention of diabetes to the world. How revealing it is that
such a concept was laid in 5000 BC.3Most importantly, the evolution of 'Preventive Cardiology'
during last 50 years deserved a special mention in this paper.4
We are well aware that India is currently passing through the
pandemic of coronary artery disease, hypertension stroke,
diabetes, and stroke. Steps to prevent and reverse this trend
were conceived by Dr. Padmavati, Dr. KS Mathur and several
others including the writer of this communication during
these years.4,5 We now have a exclusive editorial section
related to preventive cardiology in Indian Heart Journal in
order to strengthen the academic and professional aspects of
this much needed sub-specialty. Last but not the least, the
increasing trend of incorporating translational research in
cardiology practice about herbal drugs like Terminalia arjuna
(arjuna), Eugenia jumbolana (jamun), Curcuma domestica (Tur-
meric), Allium sativam (Garlic), Commiphora mukul (gum
guggal), etc.6 These herbs though currently advocated their
exact role and overall cost beneﬁt ratio is yet to be explored
and deﬁned.
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of dyslipidemia in Indian subjects: Our perspectiveDear Editor,
We read with interest the commentary by Enas A. Enas and
colleagues1 on the recently published Consensus Statement
on Management of Dyslipidemia in Indian Subjects (CSMDIS)2
and thank them for their insightful comments. It is heartening
to see that the document has generated such interest and has
drawn attention of such world-renowned leaders in the ﬁeld of
lipid management.
We are in agreement with many of the observations made
by Enas A. Enas and colleagues about the current understand-
ing of the role of statin therapy in reducing cardiovascular (CV)
morbidity and mortality. As highlighted by them, there is
unequivocal evidence to show that statins are currently the
most powerful pharmacological agents available to reduce CV
risk. More importantly, the beneﬁcial effects of statins are
observed in direct proportion to the baseline CV risk and occur
regardless of the low-density lipoprotein cholesterol (LDLC)
levels. Accordingly, most guidelines today recommend initi-
ating statin therapy based on the estimated CV risk rather than
the absolute LDLC levels. We also agree that there is now
increasing data to suggest that lifetime CV risk may be a more
appropriate metric, rather than the short-term (i.e. 10-years)
CV risk, for guiding management decisions in primaryprevention of CV disease, particularly in young individuals.
However, we wish to emphasize that there is currently no
validated risk assessment tool available for estimating short-
term or lifetime CV risk in Indians. The risk assessment
algorithm proposed by the International Atherosclerosis
Society (IAS)3 is simple to use but its use in Indians has
practical limitations, as highlighted below. In addition, we also
notice that the interpretation by Enas A. Enas et al. of the
recommendations for initiating statin therapy is different
from what has actually been proposed in the CSMDIS. We
discuss below these issues in greater detail.
1. IAS algorithm for estimation of lifetime CV
risk
The algorithm proposed by the IAS for estimating lifetime CV
risk was ﬁrst developed by Lloyd-Jones et al. based on the
Framingham study data.4 This algorithm considers only four
risk factors – diabetes, smoking, systolic blood pressure (SBP),
and total cholesterol (TC). Both diabetes and smoking are
considered to be major risk factors, whereas SBP and TC are
graded as minor, moderate, and major risk factors depending
on the actual levels (SBP: minor – 120–139 mmHg, moderate –
140–159 mmHg, and major – >160 mmHg; TC: minor – 180–
199 mg/dL, moderate – 200–239 mg/dL, and major – >240 mg/
dL). Based on the number of minor, moderate, and major risk
factors, lifetime CV risk can be estimated in any individual. For
nonwhites, the IAS document also provides appropriate
ethnic-speciﬁc calibration factors in order to derive more
accurate risk estimates in different population groups. Thus,
IAS risk algorithm is simple to use, does not require elaborate
laboratory testing, and is well suited for clinic-based estima-
tion of CV risk.
